AstraZeneca Plc - רווח למניה ב-12 החודשים האחרונים AZN

High accountability for scientific breakthroughs creates reputational challenges for AstraZeneca PLC (AZN). The current YoY EPS shift over the last 12 months demonstrates a support zone where the value of 17.50 expresses the metric level. Exclusive oncology patents and inelastic demand for therapy, along with the pricing power to recover medical investments, ensure stability.

This indicator measures the relative change in earnings per share over the last twelve months, allowing for an assessment of real capital generation efficiency. The trend of this metric serves as a leading signal for investors to revise the asset's fair value. By analyzing the net income per share YoY ttm growth rate chart, one can identify deviations of actual income from projected values. For AstraZeneca PLC (AZN), such efficiency directly depends on the implementation of robotic screening and logistics automation, which reduce development costs.